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Abstract
Background: Neurolymphomatosis (NL) is an extremely rare disease and tracheal asphyxia due to NL has not been
previously reported.
Case Presentation: A 54-year-old Chinese woman with a history of diffuse large B-cell lymphoma in her first
complete remission developed peripheral neuropathy and tracheal asphyxia. Neurolymphomatosis involving the
right brachial plexus and the right vagus nerve was demonstrated by PET/CT, but not by MRI. She underwent
urgent tracheotomy and impact chemotherapy using rituximab combined with high dose methotrexate and
involved field radiotherapy. She achieved a second complete remission.
Conclusion: PET/CT plays valuable role in differentiating NL from other neuropathies in patients with lymphoma.
Complete remission can be achieved in NL due to large B-cell lymphoma.
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Background
Neurolymphomatosis (NL) is an extremely rare disease
that can be caused by T cell, B cell or NK cell lymph-
oma, but most commonly B cell lymphoma. It is charac-
terized by lymphoma cells directly infiltrating cranial
nerve, peripheral nerve, nerve root and nerve plexus. NL
may occur primary in the peripheral nervous system or
occur as a part of systemic lymphoma [1–3]. NL may in-
volve different parts of the peripheral nervous system,
but simultaneous involvement of brachial plexus nerve
and vagus nerve has not been reported in the literature.
Here we report one such a case of NL simultaneously in-
volving brachial plexus nerve and vagus that caused a
medical emergency of vocal cord paralysis and trachea
asphyxia.
Case presentation
 A 54 years old female first presented to hematology
department of West China Hospital in November
2012 with numbness and pain of right upper
extremity lasting for 2 months. She denied any past
medical history. A 5 × 5 cm mass in upper outer
quadrant of right breast was palpated during the
physical examination. A neurological examination
showed diminished flexion and extension of right
fingers. Electromyogram (EMG) showed peripheral
neurogenic damage of right upper extremity. Fine
needle aspiration of the mass revealed some
atypical cells scattered or focally infiltrated in the
breast stroma. Immunohistochemistry of the
atypical cells showed diffuse large B cell lymphoma
(DLBCL). CT scan of chest and bone marrow
studies were negative. Cerebrospinal fluid (CSF)
analysis showed no nucleated cells, protein 0.56 g/L,
normal chlorides and glucose. A flow cytometry
examination showed no abnormal cells. She received
2 courses R-hyperCVAD(rituximab + scheme A:
cyclophosphamide + vindesine + doxorubicin +
dexamethasone/scheme B: methotrexate + cytarabine),
2 courses R-CHOP (rituximab + cyclophosphamide +
vindesine + liposomal doxorubicin + prednisone)
and 4 times intrathecal preventive chemotherapy
(methotrexate + cytarabine + dexamethasone).
Protein level of CSF fluctuated between 0.54-0.61 g/L
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and no abnormal cell was detected by flow cytometry.
She was considered in complete remission. The
patient was stable during regular follow-ups.
In February 2014, right upper extremity numbness
reoccurred and developed nonproductive cough, and short-
ness of breath which worsened at night. She was hospital-
ized. Tactile hypoesthesia and hypoalgesia of right forearm
and dorsal ulnar side of right palm were also noted again.
Her lungs were clear by auscultation and a chest CT scan
was normal. She was given an empirical treatment using
antibiotics and glucocorticoid. Her symptoms deteriorated.
She developed marked numbness and severe pain in the
right arm, also strength reduction and limited activities. She
showed paroxysmal choke to cough and hoarse voice.
Twenty days after admission she developed acute respira-
tory distress and stridor. An urgent laryngoscopy revealed
bilateral vocal cord paralysis and laryngeal obstruction. An
emergency tracheotomy was performed due to the trachea
asphyxia. Enhanced MRIs of head neck and thorax were
unremarkable (Fig. 1). PET/CT, however, showed significant
abnormally in the area of the right vagus nerve running
zone and right brachial plexus running zone, indicating
tumor invasion (Figs. 2 and 3). CSF protein level was
0.52 g/L and no abnormal cell was detected by flow cytom-
etry. Considering the patient’s medical history of lymph-
oma, symptoms and signs as well as the PET/CT results, a
diagnosis of peripheral neurolymphomatosis (involving the
right brachial plexus nerve, vagus nerve) and extranodal re-
lapse of DLBCL was established after other factors, such as
chemotherapy, infections, tumor compression and paraneo-
plastic neuropathy had been taken into account.
The patient was given five courses R-DHAP(rituximab +
cisplatin + cytarabine + dexamethasone) and high dose
methotrexate impact chemotherapy. The patient received
30-35Gy involved field radiotherapy. All her symptoms
resolved and her tracheostomy tube was removed. A
follow-up PET/CT showed complete remission of the
tumor involvement in the right vagus and right brachial
plexus nerve (Fig. 4). She remains stable as of now.
Discussion
Neurolymphomatosis (NL) is a rare condition with lymph-
oma infiltrating parts of the peripheral nerve system includ-
ing cranial nerves. Only a few cases have been reported and
the exact incidence is unclear. It was estimated that NL
may occur in 0.2 % of all non-Hodgkin’s lymphoma (NHL)
[1]. NHL is responsible for over 90 % of NL and NL rarely
occurs in Hodgkin’s lymphoma or lymphoid leukemia. It
has diverse clinical manifestations depending on the loca-
tion of involvement. Delayed diagnosis or misdiagnosis is
common and there is significant variations in treatment re-
sponse and prognosis [1–4].
NL may affect the peripheral nerves, nerve roots and
cranial nerves. Multiple nerve involvement is more com-
mon than single nerve involvement. Lumbosacral plexus
nerve, horsetail nerve and sciatic nerve are common sites
of involvement [5–7]. In this case the NL occurred during
her large B-cell lymphoma relapse and manifested as bra-
chial plexus and vagus nerve. The tumor infiltration in the
peripheral nervous system caused life-threatening bilateral
vocal cord paralysis and acute upper and real obstruction,
which resolved after chemo and radiation therapy of her
underlying large B-cell lymphoma. To our knowledge,
such an acute airway obstruction as a complication of NL
has not been previously reported in the literature.
The differential diagnosis of neurological symptoms in
patients with lymphoma includes inflammatory neur-
opathy, drug-induced neuropathy, tumor compression
and paraneoplastic syndrome [8]. It is also important to
include NL in the differential diagnosis. Electromyog-
raphy is sensitive to detecting peripheral neuropathy,
but it is not specific for NL. Direct nerve biopsy is con-
sidered the the gold standard for the diagnosis [7]. How-
ever, it is invasive and false negative results occur due to
sampling errors. Ramirez-Zamora [9] reported 1 case of
NL with negative nerve biopsy that was later confirmed
by autopsy. NL is easily misdiagnosed or missed due to
its rarity and complex clinical manifestations. An earlier
retrospective study showed that about half of the cases
were only diagnosed by autopsy [1]. Casselberry [10] re-
ported one 64-year-old NL patient presented with aggravat-
ing neurological dysfunction that had been misdiagnosed as
Guillain-Barré syndrome and inflammatory demyelination.
The patient died after 3 months of ineffective treatment
and was later found to have NL by autopsy.
Fig. 1 MRIs of nerve plexus showing no apparent changes
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Fig. 2 PET/CT images before treatment showing involvement of right vagus nerve and brachial plexus (detailed images). a, b, c show
abnormally high glucose metabolism area of the right vagus nerve running zone; d, e, f show abnormally high glucose metabolism area of
right brachial plexus running zone; a, d are coronal sections; b, e are sagittal sections; c,f are cross sections; white arrows direct at lesions
in nerves
Fig. 3 PET/CT before treatment showing involvement of right vagus nerve and brachial plexus (whole body images). Wide white arrow indicates
high glucose metabolism area of the right vagus nerve running zone; fine white arrow indicates high glucose metabolism area of the right
brachial plexus running zone
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About 60 % of patients with NL per reported to have
elevated protein level of CSF [2]. Repeated CSF examina-
tions of our case found slightly elevated protein as well.
However this is nonspecific and is sensitive. Enhanced
MRI is a very useful tool in neurology practice. However
it appears to have limited role in detecting NL peripheral
nerve involvement, as demonstrated in our case report.
PET/CT is far more superior than MRI. It is generally
believed that MRI has lower sensitivity than PET/CT de-
pending on the thickening of involved nerve, nerve root/
bundle with or without contrast enhancement [1, 2].
PET/CT has higher sensitivity and specificity for NL and
the abnormally high glucose metabolism can be used to
follow therapeutic response [11–13]. We feel that a PET/
CT should be performed in all patients suspected of NL. If
a convincingly positive test result is obtained, the treat-
ment for the underlying lymphoma should be instituted
immediately without a nerve biopsy.
The prognosis of NL varies greatly among different pa-
tients. It’s reported that the median survival time was ten
months and 3 year overall survival rate was 24 % [2]. One
case was reported to have survived over 31 years [14]. Cur-
rently high dose methotrexate plus involved field radiother-
apy is the treatment of choice for NL [1–3, 7]. Rituximab,
hematopoietic stem cell transplantation and plasma ex-
change have also been tried to treat NL with variable suc-
cess [3, 11, 15]. We used 5 cycles of rituximab combined
with high dose methotrexate impact chemotherapy for this
patient who achieved complete clinical remission based on
her symptoms and follow-up PET/CT studies. However
her long-term survival needs further observation.
Conclusion
NL is a rare complication of lymphoma with highly vari-
able clinical manifestations depending on the locations
of peripheral nerve involvement. Early diagnosis can be
challenging. EMG and CSF protein level may be helpful
but nonspecific. Enhanced MRI is of limited value. PET/
CT appears to be sensitive and specific for NL diagnosis.
Complete remission of lymphoma can still be achieved
despite the development of NL.
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Fig. 4 Whole body PET/CT after treatment showing resolution of high metabolic foci
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